We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Affirms Marketing Exclusivity for Shire’s ADHD Drug Vyvanse
Court Affirms Marketing Exclusivity for Shire’s ADHD Drug Vyvanse
November 23, 2010
A U.S. appeals court has upheld Shire’s right to five-year marketing exclusivity for its attention deficit hyperactivity disorder treatment Vyvanse (lisdexamfetamine dimesylate), dashing Actavis’ hopes of introducing a generic version of the drug.